[{"id":"c31fe31a-3823-4e8c-81cc-892c70bccfed","acronym":"","url":"https://clinicaltrials.gov/study/NCT07206849","created_at":"2025-10-11T01:31:02.610Z","updated_at":"2025-10-11T01:31:02.610Z","phase":"Phase 2","brief_title":"Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)","source_id_and_acronym":"NCT07206849","lead_sponsor":"Nationwide Children's Hospital","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ojemda (tovorafenib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 79","initiation":"Initiation: 03/01/2026","start_date":" 03/01/2026","primary_txt":" Primary completion: 03/01/2030","primary_completion_date":" 03/01/2030","study_txt":" Completion: 03/01/2037","study_completion_date":" 03/01/2037","last_update_posted":"2025-10-03"},{"id":"42d928bf-01a8-4f38-bc3e-dbcbf7fa205e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06161974","created_at":"2023-12-08T22:16:35.701Z","updated_at":"2025-02-25T13:41:56.353Z","phase":"Phase 2","brief_title":"Study of Olutasidenib and Temozolomide in HGG","source_id_and_acronym":"NCT06161974","lead_sponsor":"Rigel Pharmaceuticals","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 mutation","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Rezlidhia (olutasidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 03/01/2025","start_date":" 03/01/2025","primary_txt":" Primary completion: 06/01/2029","primary_completion_date":" 06/01/2029","study_txt":" Completion: 06/01/2035","study_completion_date":" 06/01/2035","last_update_posted":"2025-02-21"},{"id":"70012bdf-9a68-4791-98f7-f3a645c2ba06","acronym":"","url":"https://clinicaltrials.gov/study/NCT04295759","created_at":"2021-01-18T20:50:32.592Z","updated_at":"2025-02-25T14:01:55.137Z","phase":"Phase 1","brief_title":"INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas","source_id_and_acronym":"NCT04295759","lead_sponsor":"Pediatric Brain Tumor Consortium","biomarkers":" HER-2 • CD4 • ADAM10","pipe":"","alterations":" ","tags":["HER-2 • CD4 • ADAM10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e aderbasib (INCB7839)"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 07/27/2020","start_date":" 07/27/2020","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2025-02-19"},{"id":"b568f31d-6b2b-46ca-879f-a90916765687","acronym":"","url":"https://clinicaltrials.gov/study/NCT05099003","created_at":"2021-10-29T14:53:11.674Z","updated_at":"2025-02-25T14:08:27.717Z","phase":"Phase 1/2","brief_title":"A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)","source_id_and_acronym":"NCT05099003","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF • IDH1","pipe":" | ","alterations":" BRAF mutation • BRAF V600 • IDH1 mutation","tags":["BRAF • IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600 • IDH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xpovio (selinexor)"],"overall_status":"Suspended","enrollment":" Enrollment 210","initiation":"Initiation: 05/31/2022","start_date":" 05/31/2022","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-02-18"},{"id":"09faeec2-6d19-4e99-bfa8-ce9ad5372038","acronym":"","url":"https://clinicaltrials.gov/study/NCT05843253","created_at":"2023-05-06T15:04:11.203Z","updated_at":"2025-02-25T14:09:40.595Z","phase":"Phase 2","brief_title":"Study of Ribociclib and Everolimus in HGG and DIPG","source_id_and_acronym":"NCT05843253","lead_sponsor":"Nationwide Children's Hospital","biomarkers":" PIK3CA • PTEN • CDKN2A • RB1 • CCND1 • CDK4 • CDKN2B • PIK3R1 • CDK6 • CCND2 • CDKN2C","pipe":" | ","alterations":" PIK3CA mutation • CDKN2A deletion","tags":["PIK3CA • PTEN • CDKN2A • RB1 • CCND1 • CDK4 • CDKN2B • PIK3R1 • CDK6 • CCND2 • CDKN2C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • CDKN2A deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Kisqali (ribociclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 08/22/2024","start_date":" 08/22/2024","primary_txt":" Primary completion: 08/28/2028","primary_completion_date":" 08/28/2028","study_txt":" Completion: 08/28/2034","study_completion_date":" 08/28/2034","last_update_posted":"2025-02-17"},{"id":"597196ff-832d-47d8-abb2-6fd446401e06","acronym":"ACNS1721","url":"https://clinicaltrials.gov/study/NCT03581292","created_at":"2021-01-18T17:37:11.394Z","updated_at":"2025-02-25T16:52:13.824Z","phase":"Phase 2","brief_title":"Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations","source_id_and_acronym":"NCT03581292 - ACNS1721","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":" | ","alterations":" IDH wild-type","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • veliparib (ABT-888)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 11/06/2018","start_date":" 11/06/2018","primary_txt":" Primary completion: 03/31/2023","primary_completion_date":" 03/31/2023","study_txt":" Completion: 10/16/2025","study_completion_date":" 10/16/2025","last_update_posted":"2025-02-04"},{"id":"bca1dafe-5b6f-43a8-b486-61c7b69a4e9d","acronym":"5G-RUBY","url":"https://clinicaltrials.gov/study/NCT06630260","created_at":"2025-02-25T19:12:02.371Z","updated_at":"2025-02-25T19:12:02.371Z","phase":"Phase 1/2","brief_title":"5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours","source_id_and_acronym":"NCT06630260 - 5G-RUBY","lead_sponsor":"Institute of Cancer Research, United Kingdom","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Avmapki (avutometinib) • Fakzynja (defactinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 182","initiation":"Initiation: 11/15/2024","start_date":" 11/15/2024","primary_txt":" Primary completion: 09/30/2029","primary_completion_date":" 09/30/2029","study_txt":" Completion: 09/30/2030","study_completion_date":" 09/30/2030","last_update_posted":"2025-01-22"},{"id":"6e3accdd-5a43-478f-a02d-784bf9cd8ce5","acronym":"NCI-2018-00876","url":"https://clinicaltrials.gov/study/NCT03528642","created_at":"2021-01-18T17:22:22.349Z","updated_at":"2024-07-02T16:34:37.431Z","phase":"Phase 1","brief_title":"Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma","source_id_and_acronym":"NCT03528642 - NCI-2018-00876","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH1 mutation • IDH2 mutation","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • telaglenastat (CB-839)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 05/01/2019","start_date":" 05/01/2019","primary_txt":" Primary completion: 12/05/2024","primary_completion_date":" 12/05/2024","study_txt":" Completion: 12/05/2024","study_completion_date":" 12/05/2024","last_update_posted":"2024-06-07"},{"id":"8420d34e-5720-4abb-8b0f-9d930a4e3baa","acronym":"","url":"https://clinicaltrials.gov/study/NCT03212274","created_at":"2021-01-18T15:50:38.215Z","updated_at":"2024-07-02T16:35:02.706Z","phase":"Phase 2","brief_title":"Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations","source_id_and_acronym":"NCT03212274","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH2 mutation • IDH1 R132H • IDH2 R172K • IDH1 R132C • IDH1 R132 • IDH1 R132G • IDH2 R140Q • IDH1 R132L • IDH1 R132S • IDH1 R132V • IDH2 R172 • IDH2 R172G","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • IDH1 R132H • IDH2 R172K • IDH1 R132C • IDH1 R132 • IDH1 R132G • IDH2 R140Q • IDH1 R132L • IDH1 R132S • IDH1 R132V • IDH2 R172 • IDH2 R172G"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 145","initiation":"Initiation: 01/30/2019","start_date":" 01/30/2019","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 07/31/2024","study_completion_date":" 07/31/2024","last_update_posted":"2024-05-17"},{"id":"87923196-97d9-4e54-a07f-3d2558fab429","acronym":"","url":"https://clinicaltrials.gov/study/NCT02101905","created_at":"2021-01-18T09:41:49.492Z","updated_at":"2024-07-02T16:35:07.246Z","phase":"Phase 1","brief_title":"Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma","source_id_and_acronym":"NCT02101905","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR amplification","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lapatinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 03/13/2014","start_date":" 03/13/2014","primary_txt":" Primary completion: 10/19/2021","primary_completion_date":" 10/19/2021","study_txt":" Completion: 10/19/2024","study_completion_date":" 10/19/2024","last_update_posted":"2024-04-29"},{"id":"ea3578e9-dece-4f8e-8a45-a557cb4ab371","acronym":"","url":"https://clinicaltrials.gov/study/NCT02192359","created_at":"2021-01-18T10:14:16.362Z","updated_at":"2024-07-02T16:35:07.217Z","phase":"Phase 1","brief_title":"Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas","source_id_and_acronym":"NCT02192359","lead_sponsor":"City of Hope Medical Center","biomarkers":" UGT1A1","pipe":"","alterations":" ","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 03/07/2016","start_date":" 03/07/2016","primary_txt":" Primary completion: 02/21/2022","primary_completion_date":" 02/21/2022","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2024-04-29"},{"id":"07f72434-f6fa-47b7-ba9f-45d495429259","acronym":"","url":"https://clinicaltrials.gov/study/NCT01358058","created_at":"2021-01-18T05:33:17.210Z","updated_at":"2024-07-02T16:35:12.677Z","phase":"","brief_title":"Proton Radiation Therapy for Gliomas","source_id_and_acronym":"NCT01358058","lead_sponsor":"Massachusetts General Hospital","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 mutation","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 05/01/2011","start_date":" 05/01/2011","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2024-03-27"},{"id":"2a616249-11ac-4d5e-bcef-f68f308c0720","acronym":"","url":"https://clinicaltrials.gov/study/NCT06214689","created_at":"2024-01-19T19:20:28.219Z","updated_at":"2024-07-02T16:35:17.372Z","phase":"","brief_title":"IDH1 and OCT4 in High Grade Astrocytoma","source_id_and_acronym":"NCT06214689","lead_sponsor":"Assiut University","biomarkers":" IDH1 • POU5F1","pipe":"","alterations":" ","tags":["IDH1 • POU5F1"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 05/01/2024","start_date":" 05/01/2024","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2024-02-28"},{"id":"9e7aadce-c10d-42e5-89cd-07b8fcf58f56","acronym":"","url":"https://clinicaltrials.gov/study/NCT03896568","created_at":"2021-01-18T19:11:27.737Z","updated_at":"2024-07-02T16:35:17.987Z","phase":"Phase 1","brief_title":"MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma","source_id_and_acronym":"NCT03896568","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IDH1","pipe":" | ","alterations":" IDH wild-type","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tasadenoturev (DNX-2401)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 02/12/2019","start_date":" 02/12/2019","primary_txt":" Primary completion: 09/30/2027","primary_completion_date":" 09/30/2027","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2024-02-23"},{"id":"1f17a218-bc5e-4d55-a40a-94144604e122","acronym":"","url":"https://clinicaltrials.gov/study/NCT02323880","created_at":"2021-01-18T11:01:20.161Z","updated_at":"2024-07-02T16:35:24.780Z","phase":"Phase 1","brief_title":"Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas","source_id_and_acronym":"NCT02323880","lead_sponsor":"Children's Oncology Group","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xpovio (selinexor)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 59","initiation":"Initiation: 10/30/2015","start_date":" 10/30/2015","primary_txt":" Primary completion: 09/30/2022","primary_completion_date":" 09/30/2022","study_txt":" Completion: 09/22/2024","study_completion_date":" 09/22/2024","last_update_posted":"2024-01-01"},{"id":"52345c9c-541e-41a7-bdf5-45f77ff791e9","acronym":"","url":"https://clinicaltrials.gov/study/NCT02800486","created_at":"2021-01-18T13:44:19.209Z","updated_at":"2024-07-02T16:35:29.924Z","phase":"Phase 2","brief_title":"Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA","source_id_and_acronym":"NCT02800486","lead_sponsor":"Northwell Health","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR overexpression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab)"],"overall_status":"Recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 05/01/2016","start_date":" 05/01/2016","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2023-11-08"},{"id":"809a0473-89c4-4bc7-8faf-bd2441b7e0a3","acronym":"","url":"https://clinicaltrials.gov/study/NCT02549833","created_at":"2021-01-18T12:20:05.485Z","updated_at":"2024-07-02T16:35:34.594Z","phase":"Phase 1","brief_title":"Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma","source_id_and_acronym":"NCT02549833","lead_sponsor":"Jennie Taylor","biomarkers":" CD8 • CXCL10 • CD4","pipe":" | ","alterations":" CXCL10 expression","tags":["CD8 • CXCL10 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CXCL10 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GBM6-AD • Hiltonol (poly-ICLC)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 10/17/2016","start_date":" 10/17/2016","primary_txt":" Primary completion: 08/15/2022","primary_completion_date":" 08/15/2022","study_txt":" Completion: 08/31/2024","study_completion_date":" 08/31/2024","last_update_posted":"2023-10-05"},{"id":"4bcfb962-b8dd-4377-826e-bc8e7b62607e","acronym":"CYNK001GBM02","url":"https://clinicaltrials.gov/study/NCT05218408","created_at":"2022-02-05T18:28:25.292Z","updated_at":"2024-07-02T16:35:55.355Z","phase":"Phase 1/2","brief_title":"CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type","source_id_and_acronym":"NCT05218408 - CYNK001GBM02","lead_sponsor":"Celularity Incorporated","biomarkers":" IDH1","pipe":" | ","alterations":" IDH wild-type","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • taniraleucel (CYNK-001)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/08/2022","start_date":" 03/08/2022","primary_txt":" Primary completion: 02/01/2024","primary_completion_date":" 02/01/2024","study_txt":" Completion: 05/01/2024","study_completion_date":" 05/01/2024","last_update_posted":"2023-02-16"},{"id":"09433bad-7c17-41a7-b1ca-4ac19bbc5a86","acronym":"STEAM","url":"https://clinicaltrials.gov/study/NCT03224104","created_at":"2021-01-18T15:54:47.667Z","updated_at":"2024-07-02T16:36:09.663Z","phase":"Phase 1","brief_title":"Study of TG02 in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma","source_id_and_acronym":"NCT03224104 - STEAM","lead_sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","biomarkers":" IDH1 • IDH2 • MCL1 • CDK9","pipe":" | ","alterations":" IDH1 R132H • IDH1 R132","tags":["IDH1 • IDH2 • MCL1 • CDK9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132H • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • zotiraciclib (TG02)"],"overall_status":"Completed","enrollment":" Enrollment 71","initiation":"Initiation: 06/12/2018","start_date":" 06/12/2018","primary_txt":" Primary completion: 05/05/2022","primary_completion_date":" 05/05/2022","study_txt":" Completion: 05/05/2022","study_completion_date":" 05/05/2022","last_update_posted":"2022-05-31"},{"id":"9c28c66f-c3b4-4633-96d1-74a5ed78d628","acronym":"","url":"https://clinicaltrials.gov/study/NCT02942264","created_at":"2021-01-18T14:26:49.487Z","updated_at":"2024-07-02T16:36:23.846Z","phase":"Phase 2","brief_title":"Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma","source_id_and_acronym":"NCT02942264","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • ATRX","pipe":"","alterations":" ","tags":["TP53 • ATRX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • zotiraciclib (TG02)"],"overall_status":"Completed","enrollment":" Enrollment 53","initiation":"Initiation: 12/14/2016","start_date":" 12/14/2016","primary_txt":" Primary completion: 08/26/2020","primary_completion_date":" 08/26/2020","study_txt":" Completion: 08/26/2020","study_completion_date":" 08/26/2020","last_update_posted":"2021-09-28"},{"id":"a2af5fdc-dd4d-4dbc-a6a6-5eea7bc19593","acronym":"","url":"https://clinicaltrials.gov/study/NCT01392209","created_at":"2021-01-18T05:42:58.214Z","updated_at":"2024-07-02T16:36:53.276Z","phase":"Phase 1","brief_title":"Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma","source_id_and_acronym":"NCT01392209","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" MGMT","pipe":" | ","alterations":" MGMT promoter methylation","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGMT promoter methylation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab)"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 07/08/2011","start_date":" 07/08/2011","primary_txt":" Primary completion: 11/15/2019","primary_completion_date":" 11/15/2019","study_txt":" Completion: 11/15/2019","study_completion_date":" 11/15/2019","last_update_posted":"2019-11-22"},{"id":"3394a8c8-2d3a-47af-8e85-851b55f69cb0","acronym":"CerebralEDV","url":"https://clinicaltrials.gov/study/NCT02766699","created_at":"2021-01-18T13:34:05.356Z","updated_at":"2024-07-02T16:36:56.125Z","phase":"Phase 1","brief_title":"A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent Glioblastoma Multiforme (GBM)","source_id_and_acronym":"NCT02766699 - CerebralEDV","lead_sponsor":"Engeneic Pty Limited","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vectibix (panitumumab) • doxorubicin hydrochloride • doxorubicin encapsulated nanocells (EGFREDVDox)"],"overall_status":"Unknown status","enrollment":" Enrollment 20","initiation":"Initiation: 10/25/2016","start_date":" 10/25/2016","primary_txt":" Primary completion: 12/01/2019","primary_completion_date":" 12/01/2019","study_txt":" Completion: 06/01/2020","study_completion_date":" 06/01/2020","last_update_posted":"2019-08-29"},{"id":"98586a6d-8fa3-4c84-a3a4-dac719a7444a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01967758","created_at":"2021-01-18T08:56:41.914Z","updated_at":"2024-07-02T16:37:07.758Z","phase":"Phase 1","brief_title":"Phase I Study of Safety and Immunogenicity of ADU-623","source_id_and_acronym":"NCT01967758","lead_sponsor":"Providence Health \u0026 Services","biomarkers":" CTAG1B","pipe":"","alterations":" ","tags":["CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ADU-623"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 01/08/2014","start_date":" 01/08/2014","primary_txt":" Primary completion: 06/18/2018","primary_completion_date":" 06/18/2018","study_txt":" Completion: 08/15/2018","study_completion_date":" 08/15/2018","last_update_posted":"2018-08-17"},{"id":"0fed4813-2327-42f4-8f7e-67b0a8ca6e06","acronym":"","url":"https://clinicaltrials.gov/study/NCT00679354","created_at":"2021-01-18T02:32:24.165Z","updated_at":"2024-07-02T16:37:08.366Z","phase":"Phase 2","brief_title":"Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy","source_id_and_acronym":"NCT00679354","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABCB1 • ABCG2","pipe":"","alterations":" ","tags":["ABCB1 • ABCG2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cilcane (cilengitide)"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 06/01/2008","start_date":" 06/01/2008","primary_txt":" Primary completion: 10/01/2010","primary_completion_date":" 10/01/2010","study_txt":" Completion: 07/01/2011","study_completion_date":" 07/01/2011","last_update_posted":"2018-08-01"}]